181 related articles for article (PubMed ID: 11968790)
1. [Development of HIV vaccines].
Shibata R
Nihon Rinsho; 2002 Apr; 60(4):790-7. PubMed ID: 11968790
[TBL] [Abstract][Full Text] [Related]
2. Development of prophylactic AIDS vaccines: the current state of affairs.
Hanke T
Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
[TBL] [Abstract][Full Text] [Related]
5. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
6. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
[No Abstract] [Full Text] [Related]
7. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
Emini EA; Koff WC
Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
[No Abstract] [Full Text] [Related]
8. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
[TBL] [Abstract][Full Text] [Related]
9. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
[No Abstract] [Full Text] [Related]
10. HIV vaccine efficacy trials: towards the future of HIV prevention.
Kim D; Elizaga M; Duerr A
Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
[TBL] [Abstract][Full Text] [Related]
11. AIDS vaccines: back to 'plan A'.
Check E
Nature; 2003 Jun; 423(6943):912-4. PubMed ID: 12827164
[No Abstract] [Full Text] [Related]
12. AIDS vaccine development.
Agosto M; Allan J; Benson C; Berger EA; Blumenthal R; Burton D; Clements J; Coffin J; Connor R; Cullen B; Desrosiers R; Dimitrov D; Doms R; Emerman M; Feinberg M; Fultz P; Gerard C; Gonsalves G; Haase A; Haigwood N; Hirsch V; Ho D; Hoxie JA; Hu SL; Zingale D
Science; 1998 May; 280(5365):803, 804-5. PubMed ID: 9599148
[No Abstract] [Full Text] [Related]
13. AIDS research. Debate begins over new vaccine trials.
Cohen J
Science; 2001 Sep; 293(5537):1973. PubMed ID: 11557856
[No Abstract] [Full Text] [Related]
14. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.
Haynes BF; Yasutomi Y; Torres JV; Gardner MB; Langlios AJ; Bolognesi DP; Matthews TJ; Scearce RM; Jones DM; Moody MA
Trans Assoc Am Physicians; 1993; 106():33-41. PubMed ID: 8036743
[No Abstract] [Full Text] [Related]
15. An anti-idiotype vaccine for AIDS based on the HIV receptor.
Dalgleish AG
Ann Ist Super Sanita; 1991; 27(1):27-31. PubMed ID: 1683525
[TBL] [Abstract][Full Text] [Related]
16. [HIV/AIDS vaccines: heading for new vaccine approaches?].
Girard MP
Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
[TBL] [Abstract][Full Text] [Related]
17. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
18. Public health. AIDS vaccine still alive as booster after second failure in Thailand.
Cohen J
Science; 2003 Nov; 302(5649):1309-10. PubMed ID: 14631004
[No Abstract] [Full Text] [Related]
19. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
20. AIDS vaccine: efficacy, safety and ethics.
Veljkovic V; Veljkovic N; Glisic S; Ho MW
Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]